New research indicates that being born with one copy of the sickle gene puts an individual at elevated risk for developing kidney failure requiring dialysis. The findings, which appear in an upcoming issue of the Journal of the American Society of Nephrology (JASN), may have important public policy implications for genetic counseling for individuals with sickle cell trait (SCT).
Hemoglobin variants, including SCT and hemoglobin C trait, are common in African Americans. These variants are thought to have persisted throughout evolution due to their protective effects against malaria. Affected individuals do not have a disease: they only carry 1 copy of a hemoglobin gene variant, and unlike individuals with 2 copies of the variant, they do not experience symptoms. Prior evidence suggested that the variants may play a role in chronic kidney disease in blacks, however, the association of these hemoglobin traits to progression to kidney failure requiring dialysis was unknown.
To investigate this potential link, a team led by Rakhi Naik, MD, MHS (Johns Hopkins University) and Marguerite Irvin, PhD (University of Alabama at Birmingham) analyzed data from a large population-based study, the REasons for Geographic and Racial Differences in Stroke (REGARDS) study. The researchers evaluated 9909 African Americans, of whom 739 had SCT and 243 had hemoglobin C trait.
Among the findings:
• Kidney failure requiring dialysis developed in 40 of 739 (5.4%) individuals with SCT, 6 of 243 (2.5%) individuals with hemoglobin C trait, and 234 of 8927 (2.6%) noncarriers during a median follow-up of 6.5 years.
• The incidence rate for kidney failure was 8.5 per 1000 person-years for participants with SCT and 4.0 per 1000 person-years for noncarriers.
• Compared with individuals without SCT, individuals with SCT had a twofold increased risk of developing kidney failure.
• SCT conferred a similar degree of risk as APOL1 gene variants, which are the most widely recognized genetic contributors to kidney disease in blacks.
• Hemoglobin C trait did not associate with kidney disease or kidney failure.
The investigators noted that SCT is currently identified at birth in the United States via the Newborn Screening Program. “Although you cannot change the genes you are born with, doctors can use this information to start screening for kidney disease earlier and to aggressively treat any other risk factors you may have such as diabetes or high blood pressure,” said Dr. Naik. “We still need more studies to determine if there are other treatments that can be used to slow the progression of kidney disease specifically in individuals with sickle cell trait.”